Engensis

Phase 3Biologic

HHelixmith Co., Ltd.

Engensis is one of 120 biologic programs targeting Charcot-Marie-Tooth disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

119

Competitors

Pipeline

Status by Indication[3][1]

Indication

Charcot-Marie-Tooth DiseaseActive, not recruiting

Peripheral NeuropathyActive, not recruiting

Amyotrophic Lateral SclerosisActive, not recruiting

Diabetic NeuropathyActive, not recruiting

Charcot-Marie-Tooth DiseasePhase 1/Phase 2

Active, not recruiting

Peripheral NeuropathyPhase 3

Active, not recruiting

Amyotrophic Lateral SclerosisPhase 2

Active, not recruiting

Diabetic NeuropathyPhase 3

Active, not recruiting

Competition

Competitive Landscape

220 competitors in Amyotrophic Lateral Sclerosis

#DrugCompanyPhaseTrials

Tivicay

GSK

Phase 3

2 2

Radicava

Shionogi

Phase 3

2 3

Simdax

Orion Corporation, Orion Pharma

Phase 3

1 4

Robitussin

Ultomiris

Lithobid

SSolvay Pharmaceuticals

Phase 3

3 7

Minocin

TTriax

Phase 3

2 8

Sodium Valproate

AstraZeneca

Phase 3

1 9

BOTULINUM TOXIN TYPE B

Eisai

Phase 3

1 10

Azilect

Teva

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Amyotrophic Lateral Sclerosis2 trials

Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis

Completed·HHelixmith Co., Ltd.·Phase 2·NCT04632225·18 enrolled

A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis

Completed·HHelixmith Co., Ltd.·Phase 2·NCT05176093·8 enrolled

Peripheral Neuropathy2 trials

A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy

Completed·HHelixmith Co., Ltd.·Phase 3·NCT04873232·106 enrolled

Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral Neuropathy

Completed·HHelixmith Co., Ltd.·Phase 3·NCT04469270·162 enrolled

Diabetic Neuropathy1 trial

Phase 3 Gene Therapy for Painful Diabetic Neuropathy

Completed·HHelixmith Co., Ltd.·Phase 3·NCT02427464·507 enrolled

Charcot-Marie-Tooth disease1 trial

The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)

Completed·HHelixmith Co., Ltd.·Phase 1/2·NCT05361031·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Engensis. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Engensis compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Engensis. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Helixmith Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: HHelixmith Co., Ltd.

Engensis

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Amyotrophic Lateral Sclerosis2 trials

Peripheral Neuropathy2 trials

Diabetic Neuropathy1 trial

Charcot-Marie-Tooth disease1 trial

References

Drug Info

Quick Facts

Related News